Free Trial

Acrivon Therapeutics (ACRV) News Today

Acrivon Therapeutics logo
$6.50 +0.12 (+1.88%)
(As of 11/20/2024 ET)
HC Wainwright Analysts Decrease Earnings Estimates for ACRV
Acrivon Therapeutics, Inc. stock logo
Equities Analysts Offer Predictions for ACRV FY2024 Earnings
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Research analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now expects that the company will post earning
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital Markets
BMO Capital Markets cut their price objective on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC Wainwright
HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from Analysts
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has earned an average recommendation of "Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 1,110,000 shares, a decline of 8.3% from the September 30th total of 1,210,000 shares. Based on an average daily trading volume, of 90,900 shares, the short-interest ratio is currently 12.2 days. Approximately 5.1% of the company's shares are sold short.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 5.5% in September
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,210,000 shares, a drop of 5.5% from the September 15th total of 1,280,000 shares. Based on an average trading volume of 93,600 shares, the days-to-cover ratio is presently 12.9 days. Currently, 5.6% of the company's stock are sold short.
Acrivon Therapeutics, Inc. stock logo
Marshall Wace LLP Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
Marshall Wace LLP lifted its holdings in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 58.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 948,866 shares of the company's stock af
Acrivon Therapeutics, Inc. stock logo
Perceptive Advisors LLC Has $31.09 Million Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
Perceptive Advisors LLC lifted its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 78.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,360,858 shares of the company's stoc
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 24.3% in September
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 1,280,000 shares, a growth of 24.3% from the August 31st total of 1,030,000 shares. Currently, 5.9% of the company's shares are short sold. Based on an average daily volume of 101,600 shares, the days-to-cover ratio is currently 12.6 days.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Position Raised by Sands Capital Ventures LLC
Sands Capital Ventures LLC grew its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 28.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,122,605 shares of t
TD Cowen Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. stock logo
JMP Securities Reaffirms Market Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)
JMP Securities reiterated a "market outperform" rating and set a $17.00 price target on shares of Acrivon Therapeutics in a research report on Monday.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics' (ACRV) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of Acrivon Therapeutics in a report on Monday.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics (NASDAQ:ACRV) Raised to "Buy" at LADENBURG THALM/SH SH
LADENBURG THALM/SH SH raised Acrivon Therapeutics from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a report on Monday.
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics (NASDAQ:ACRV) Receives Buy Rating from Piper Sandler Companies
Piper Sandler Companies restated a "buy" rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Moderate Buy" by Analysts
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the com
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics (NASDAQ:ACRV) Posts Earnings Results
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.08.
Acrivon Therapeutics, Inc. stock logo
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Rating of "Moderate Buy" by Brokerages
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to th
Get Acrivon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.

Trump said you could learn something from this man (Ad)

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Here’s everything you need to know.

ACRV Media Mentions By Week

ACRV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACRV
News Sentiment

0.00

0.46

Average
Medical
News Sentiment

ACRV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACRV Articles
This Week

15

2

ACRV Articles
Average Week

Get Acrivon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ACRV) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners